CoChat
Sign Up
Cited by 169Tryptophan and brain disordersCancer survivorship and careTreatment of Major Depression

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient's Initial Affective State

Open access
Capuron, Lucile, Ravaud, Alain·1999·New England Journal of Medicine
DOI 10.1056/nejm199904293401716
Open this paper in CoChat — free accountOpen PDF

Abstract

To the Editor: The study by Leon et al. (Dec.3 issue) 1 comparing three antithrombotic-drug regimens -aspirin alone, aspirin and warfarin, and aspirin and ticlopidineafter coronary stenting showed a lower rate of stent thrombosis with aspirin and ticlopidine, although there were more hemorrhagic complications than with aspirin alone.By contrast, there were no significant differences in the incidence of neutropenia or thrombocytopenia among the three regimens (overall incidence, 0.3 percent).Despite the absence of severe hematologic dyscrasias in the study, the authors refer to reports of the risk of serious hematologic complications, such as thrombotic thrombocytopenic purpura, among patients who received ticlopidine after coronary stent placement.However, they did not mention the risk of aplastic anemia, a life-threatening condition that may be induced by ticlopidine.Recently, Yeh et al. reviewed the cases of ticlopidine-induced aplastic anemia published in the English literature, 2 and four other cases have been reported 3,4 (including one case reported by us).Ten of 23 patients died (43 percent): 7 because of infection (candidal and gram-negative sepsis) and 1 from massive gastrointestinal bleeding.The only factor significantly correlated with survival was the patients' age.Other factors, such as sex, duration of ticlopidine use, and the presence of agranulocytosis at onset, had no prognostic value. 2 Although the pathogenesis of marrow toxicity related to this drug is still unclear, both direct toxicity and immunologic effects have been proposed. 2The therapeutic use of hematopoietic growth factors has been suggested, 4 but this treatment seems to have little effect on survival. 2,3n summary, although it is an infrequent event, ticlopi-dine-induced marrow aplasia is possible, and patients and doctors should be aware of it.However, aplastic anemia, like other hematologic dyscrasias induced by ticlopidine, appears after 2 weeks of treatment, 2-4 whereas stent thrombosis generally occurs within the first 14 days after coronary stenting (a mean of 0.7 day in the study by Leon et al.). 1 So, we agree with the suggestion made by Leon et al.to shorten the duration of ticlopidine therapy after stenting to two weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199904293401716

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 1

  1. Borden EC, 1998, Semin Oncol, 25, 3

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Capuron, L., & Ravaud, A.
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
1999-04-29
Volume
340
Issue
17
Pages
1370-1370
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejm199904293401716
OpenAlex
W1986891518
Cited by
169
References
4
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 4 · 2012: 10
FWCI
5.18
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
interferon-alpha therapy, depression, affective states, treatment response prediction, interferon-induced depression
MeSH terms
Adult, Affect, Antineoplastic Agents, Depression, Female, Humans, Male, Melanoma, Psychiatric Status Rating Scales, Interferon-alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review